Key Highlights

  • Twist Bioscience shares are trading up 11.65% today to $111.04, extending a rally that began after fiscal third-quarter results were reported on August 3.
  • The company priced an upsized underwritten public offering of 3,125,000 shares at $96.00 per share, expected to raise gross proceeds of $300.0 million.
  • Fiscal third-quarter revenue rose 23% year-over-year to $118.4 million, marking the company's 14th consecutive quarter of sequential growth.
  • Management raised full-year fiscal 2026 revenue guidance to $456 million to $457 million, up from a prior range of $442 million to $447 million.
  • The company reiterated its expectation to achieve adjusted EBITDA breakeven in the fiscal fourth quarter.

What's Driving Shares Today

Twist Bioscience (NASDAQ:TWST) is a South San Francisco-based synthetic biology company founded in 2013 that has developed a proprietary silicon-based DNA synthesis platform, enabling high-throughput, cost-effective manufacturing of synthetic DNA at unprecedented precision and scale. The company offers a broad portfolio of products and services, including synthetic genes, oligo pools, NGS target enrichment tools, and antibody discovery solutions, serving over 3,800 customers globally across healthcare, biopharma, academic research, industrial chemicals, and agriculture sectors.

Shares are extending their post-earnings rally today, trading near 52-week highs, after the company priced an upsized $300 million public offering to fund research and manufacturing capacity expansion. This follows Monday's raised fiscal 2026 revenue guidance to $456 million to $457 million and 23% third-quarter revenue growth to $118.4 million, both of which beat consensus estimates.

Capital Raise to Fund Growth

The offering, upsized from its original terms, priced at $96.00 per share and is expected to close on August 6, 2026. Twist intends to use the net proceeds, together with existing cash and marketable securities, to fund research and development investments, expand manufacturing capacity, grow product offerings, and support working capital and general corporate purposes. Goldman Sachs, William Blair, Leerink Partners, and Guggenheim Securities are acting as joint book-running managers.

Investors appear to be rewarding continued execution on synthetic biology and next-generation sequencing growth alongside the company's path toward fourth-quarter adjusted EBITDA breakeven, even as the capital raise introduces some dilution considerations. DNA Synthesis and Protein Solutions revenue rose 39% to $56.6 million in the third quarter, and the company shipped products to approximately 2,650 customers during the period.

AI Drug Discovery as a Growth Driver

CEO and co-founder Emily Leproust said AI-enabled drug discovery is becoming a major growth driver as customers increasingly rely on AI models in therapeutic design, with management expressing confidence in achieving at least triple-digit order growth in both fiscal 2026 and fiscal 2027. The company also launched its Complex Genes offering after early-access customers ordered more than 1,800 constructs, adding to the broader diversification of its revenue base beyond core DNA synthesis.

Conclusion

Twist Bioscience's combination of raised guidance, a fourteenth consecutive quarter of growth, and a well-received capital raise suggests the market is increasingly confident in the company's path to sustained profitability. With shares trading near multi-year highs and broader healthcare sector strength providing an additional tailwind, today's advance reflects growing conviction that Twist's growth engine has staying power heading into fiscal 2027.

This article is for informational purposes only and does not constitute investment advice. Readers should conduct their own research before making financial decisions.